Selank

From Wikipedia, the free encyclopedia

Template:Short description

Page Module:Message box/ambox.css has no content.

Template:Cs1 config Template:Short description Page Template:Infobox drug/styles.css has no content.

Page Module:Infobox/styles.css has no content.

Selank
Lua error in package.lua at line 80: module 'Module:InfoboxImage/data' not found.
Clinical data
Other namesSelanc; L-threonyl-L-lysyl-L-prolyl-L-arginyl-L-prolylglycyl-L-Proline
Routes of
administration		Nasal muscosa, IV
Legal status
Legal statusPage Template:Plainlist/styles.css has no content.
  • In general: unscheduled
Identifiers
  • 1-[2-({1-[2-({1-[6-Amino-2-(2-amino-3-hydroxy-butyrylamino)-hexanoyl]-pyrrolidine-2-carbonyl}-amino)-5-guanidino-pentanoyl]-pyrrolidine-2-carbonyl}-amino)-acetyl]-pyrrolidine-2-carboxylic acid
CAS NumberPage Template:Plainlist/styles.css has no content.
PubChem CIDPage Template:Plainlist/styles.css has no content.
PubChem SIDPage Template:Plainlist/styles.css has no content.
IUPHAR/BPSPage Template:Plainlist/styles.css has no content.
DrugBankPage Template:Plainlist/styles.css has no content.
ChemSpiderPage Template:Plainlist/styles.css has no content.
UNIIPage Template:Plainlist/styles.css has no content.
KEGGPage Template:Plainlist/styles.css has no content.
ChEBIPage Template:Plainlist/styles.css has no content.
ChEMBLPage Template:Plainlist/styles.css has no content.
NIAID ChemDBPage Template:Plainlist/styles.css has no content.
PDB ligandPage Template:Plainlist/styles.css has no content.
CompTox Dashboard (EPA)Page Template:Plainlist/styles.css has no content.
Chemical and physical data
FormulaC33H57N11O9
Molar mass751.887 g·mol−1
3D model (JSmol)Page Template:Plainlist/styles.css has no content.
  • NCCCCC(C(=O)N1CCCC1C(=O)NC(C(=O)N2CCCC2C(=O)NCC(=O)N3CCCC3C(=O)O)CCCNC(=N)N)NC(C(C(C)O)N)=O
  • InChI=1S/C33H57N11O9/c1-19(45)26(35)29(49)41-20(8-2-3-13-34)30(50)44-17-6-11-23(44)28(48)40-21(9-4-14-38-33(36)37)31(51)43-16-5-10-22(43)27(47)39-18-25(46)42-15-7-12-24(42)32(52)53/h19-24,26,45H,2-18,34-35H2,1H3,(H,39,47)(H,40,48)(H,41,49)(H,52,53)(H4,36,37,38)/t19-,20+,21+,22+,23+,24+,26+/m1/s1 checkY
  • Key:JTDTXGMXNXBGBZ-UHFFFAOYSA-N ☒N
Data page
Template:Infobox drug/data page link
Page Template:Nobold/styles.css has no content. ☒NcheckY (what is this?)Page Template:Nobold/styles.css has no content.  (verify)

Selank (Russian: Cеланк) is a nootropic anxiolytic peptide based drug developed by the Institute of Molecular Genetics of the Russian Academy of Sciences. Selank is a heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP). It is a synthetic analogue of the human tuftsin.

Pharmacology

Selank is a synthetic analogue of the immunomodulatory peptide tuftsin; as such, it mimics many of its effects. It has been shown to modulate the expression of Interleukin-6 (IL-6) and affect the balance of T helper cell cytokines.[1] It has been shown to influence the concentration of monoamine neurotransmitters[2] and induce metabolism of serotonin.[3][4] Selank has also been found to rapidly elevate the expression of brain-derived neurotrophic factor (BDNF) in the hippocampus of rats.[5]

Selank, as well as a related peptide drug, Semax, have been found to inhibit enzymes involved in the degradation of enkephalins and other endogenous regulatory peptides, and this action may be involved in their effects.[6] It has also been found to affect the activity of carboxypeptidase H and phenylmethylsulfonylfluoride-inhibited carboxypeptidase in rat nervous system tissue.[7]

Selank has been found to produce antidepressant-like effects in animal models of depression and anhedonia.[8]

Clinical trials

In clinical studies, Selank has been investigated for its potential effects on cognitive function and anxiety.[1] It has also been compared with traditional anxiolytic drugs such as benzodiazepines and barbiturates.[9]

Selank is closely related to another nootropic drug, Semax, also developed by the Institute of Molecular Genetics in Russia. This drug is currently available in Russian and Ukrainian pharmacies.[10]

As with all lyophilized peptides, it needs refrigeration to remain stable within sterile water solutions, such as bacteriostatic water concentrations.

See also

References

Page Template:Reflist/styles.css has no content.

  1. ^ a b Page Module:Citation/CS1/styles.css has no content.Uchakina ON, Uchakin PN, Miasoedov NF, Andreeva LA, Shcherbenko VE, Mezentseva MV, et al. (2008). "[Immunomodulatory effects of selank in patients with anxiety-asthenic disorders]". Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova. 108 (5): 71–75. PMID 18577961.
  2. ^ Page Module:Citation/CS1/styles.css has no content.Narkevich VB, Kudrin VS, Klodt PM, Pokrovskiĭ AA, Kozlovskaia MM, Maĭskiĭ AI, et al. (2008). "[Effects of heptapeptide selank on the content of monoamines and their metabolites in the brain of BALB/C and C57Bl/6 mice: a comparative study]". Eksperimental'naia i Klinicheskaia Farmakologiia. 71 (5): 8–12. PMID 19093364.
  3. ^ Page Module:Citation/CS1/styles.css has no content.Semenova TP, Kozlovskiĭ II, Zakharova NM, Kozlovskaia MM (August 2010). "[Experimental optimization of learning and memory processes by selank]". Eksperimental'naia i Klinicheskaia Farmakologiia. 73 (8): 2–5. PMID 20919548.
  4. ^ Page Module:Citation/CS1/styles.css has no content.Semenova TP, Kozlovskiĭ II, Zakharova NM, Kozlovskaia MM (2009). "[Comparison of the effects of selank and tuftsin on the metabolism of serotonin in the brain of rats pretreated with PCPA]". Eksperimental'naia i Klinicheskaia Farmakologiia. 72 (4): 6–8. PMID 19803361.
  5. ^ Page Module:Citation/CS1/styles.css has no content.Inozemtseva LS, Karpenko EA, Dolotov OV, Levitskaya NG, Kamensky AA, Andreeva LA, et al. (2008). "Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo". Doklady Biological Sciences. 421: 241–243. doi:10.1134/s0012496608040066. PMID 18841804. S2CID 40709909.
  6. ^ Page Module:Citation/CS1/styles.css has no content.Kost NV, Sokolov OI, Gabaeva MV, Grivennikov IA, Andreeva LA, Miasoedov NF, et al. (2001). "Semax and selank inhibit the enkephalin-degrading enzymes from human serum". Bioorganicheskaia Khimiia (in русский). 27 (3): 180–183. doi:10.1023/A:1011373002885. PMID 11443939. S2CID 26029820.
  7. ^ Page Module:Citation/CS1/styles.css has no content.Solov'ev VB, Gengin MT, Sollertinskaia TN, Latynova IV, Zhivaeva LV (2012). "[Effect of selank on the main carboxypeptidases in the rat nervous tissue]". Zhurnal Evoliutsionnoi Biokhimii I Fiziologii (in русский). 48 (3): 254–257. PMID 22827026.
  8. ^ Page Module:Citation/CS1/styles.css has no content.Sarkisova KI, Kozlovskiĭ II, Kozlovskaia MM (2008). "[Effects of heptapeptide selank on genetically-based and situation-provoked symptoms of depression in behavior in WAG/Rij and Wistar rats, and in BALB/c mice]". Zhurnal Vysshei Nervnoi Deiatelnosti imeni I P Pavlova (in русский). 58 (2): 226–237. PMID 18661785.
  9. ^ Page Module:Citation/CS1/styles.css has no content.Zozulia AA, Neznamov GG, Siuniakov TS, Kost NV, Gabaeva MV, Sokolov OI, et al. (2008). "[Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]". Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova. 108 (4): 38–48. PMID 18454096.
  10. ^ Page Module:Citation/CS1/styles.css has no content."СЕМАКС: лекарственное средство широкого спектра действия эффективный стимулятор нервной системы" [SEMAX: a broad-spectrum drug effective stimulant of the nervous system]. Institute of Molecular Genetics (in русский). Moscow. Archived from the original on 2011-07-22.

Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found.

Template:Opioidergics

Retrieved from "https://cosmopedia.co/index.php?title=Selank&oldid=8138148"